The COHCCC Director has a wide array of advisory input to assist in planning for the Center's future and evaluating the outcomes of Center programs and policy implementation. The most important of these is the day-to-day decision-making body, the Cancer Center Executive Committee. This group consists of the traditional senior leaders of the Center, the Deputy Directors and Associate Directors, as well as several other key senior members of the Center. All plans either originate in or pass through this group. Our External Advisory Board continues to play a significant role in reviewing our plans and advising on our course of action. Our senior leaders. Program Leaders and Core Directors convene in the Cancer Center Leadership Council. The Core Facilities Oversight Committee reviews all Shared Resources activities and services to assure compliance and efficiency. Our Clinical Trials Minority Recruitment Committee is charged with increasing minority enrollment in clinical trials. Our ongoing full Cancer Center retreats and our individual Program retreats are key for promoting and facilitating key collaborations. Strategic planning is a dynamic process that is informally woven into the structure of each of our senior committees, both internal and external. In addition, COHCCC engages in a formal strategic planning process. Key leadership, including the Cancer Center Director and COH Chief Strategy Officer, meet to outline an appropriate process for the development of the objectives and an approach for the CCC strategy document. The approach includes data collection and analysis, multiple interviews with key CCC stakeholders, and an iterative review and approval process of the final deliverable. By design, the plan outlines specific objectives and goals and drives the future direction of the CCC while supporting its mission, vision and aspirations. Performance and progress of the stated goals within the plan are tracked and catalogued on an ongoing basis. Funding is requested for a small portion of the costs for our annual External Advisory Board meeting. Cancer Center retreat and Program retreats.

Public Health Relevance

Ongoing Planning and Evaluation is essential for charting the course of the Cancer Center. This goal enhances the Cancer Center's dedication to developing innovative new disease-fighting strategies in the battle against cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-31
Application #
8764859
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
31
Fiscal Year
2014
Total Cost
$27,248
Indirect Cost
$11,029
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828
Salgia, Ravi; Kulkarni, Prakash (2018) The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer. Trends Cancer 4:110-118
Yoon, Sorah; Wu, Xiwei; Armstrong, Brian et al. (2018) An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFR? Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma. Mol Ther Nucleic Acids 14:131-141
Yim, John H; Choi, Audrey H; Li, Arthur X et al. (2018) Identification of Tissue-Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics. Clin Cancer Res :
Wang, Tianyi; Fahrmann, Johannes Francois; Lee, Heehyoung et al. (2018) JAK/STAT3-Regulated Fatty Acid ?-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. Cell Metab 27:136-150.e5
Magilnick, Nathaniel; Boldin, Mark P (2018) Molecular Moirai: Long Noncoding RNA Mediators of HSC Fate. Curr Stem Cell Rep 4:158-165
Yun, Xinwei; Zhang, Keqiang; Wang, Jinhui et al. (2018) Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma. Mol Cancer Res 16:1161-1171
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520
Slavin, Thomas P; Banks, Kimberly C; Chudova, Darya et al. (2018) Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol :JCO1800328
Shahin, Sophia A; Wang, Ruining; Simargi, Shirleen I et al. (2018) Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. Nanomedicine 14:1381-1394

Showing the most recent 10 out of 1396 publications